WAVEMAN · COMPANY

MRK · Merck & Co., Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

MRK

Name: Merck & Co., Inc. (MRK) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Merck & Co., Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000310158

CONGRESS · 2FORM 144 · 9☆ WATCH

INSIDER NET · 180D

-$30.0M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

1,843

13F, latest reported quarter

REVENUE GROWTH

+1.3%

XBRL, annual

NET MARGIN

28.1%

CONVERSIONS · 180D

codes C/M, not in net · $17.1M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$30.0M over 180 days

-$30.0M over 90 days

below 91% of Pharma & Biotech

CONGRESS

2 members bought in the last year

more than 65% of Pharma & Biotech

FUNDS

1,843 funds added or opened last quarter

the highest in Pharma & Biotech

REVENUE

+1.3% year over year

below 51% of Pharma & Biotech

MARGIN

28.1% net margin

more than 91% of Pharma & Biotech

BUYBACKS

$1.6B repurchased, FY to 2026-06-30

more than 97% of Pharma & Biotech

SHORT

1.1% of shares outstanding short · 3.2 days to cover · settled 2026-07-31

below 71% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$30.0M across 5 people in 180 days.

1,843 funds added or opened positions in the latest 13F quarter, of 3,838 holders.

2 members of Congress reported buying it this year.

2 clinical trials were terminated, suspended or withdrawn in the last 90 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +81.7%

+81.7%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $30.0M sold by insiders over 180 days, 1,843 funds added last quarter, 2 Congress member(s) bought in 12 months, $30.0M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Merck & Co., Inc. insiders sold a net $30.0M of stock across 129 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Guindo Chirfi

EVP, Access, Policy & Comms

SELL

2026-08-13

10,000.0

$1.4M

DeLuca Richard R.

EVP&Pres, Merck Animal Heallth

SELL

2026-08-12

11,099.0

$1.5M

DeLuca Richard R.

EVP&Pres, Merck Animal Heallth

SELL

2026-08-12

600.0

$79.2K

Zachary Jennifer

EVP, General Counsel

SELL

2026-08-12

80,315.0

$10.7M

DeLuca Richard R.

EVP&Pres, Merck Animal Heallth

SELL

2026-08-11

7,410.0

$973.2K

129 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 124 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

226,999,837.0 sh

$29.2B

VANGUARD CAPITAL MANAGEMENT LLC

161,323,174.0 sh

$20.7B

STATE STREET CORP

120,413,256.0 sh

$15.6B

WELLINGTON MANAGEMENT GROUP LLP

86,249,283.0 sh

$11.1B

VANGUARD PORTFOLIO MANAGEMENT LLC

67,738,969.0 sh

$8.7B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

CHIRFI GUINDO

FILED 2026-08-13

$1.4M

RICHARD ROBERT DELUCA JR

FILED 2026-08-12

$1.5M

JENNIFER L ZACHARY

FILED 2026-08-12

$10.7M

RICHARD ROBERT DELUCA JR

FILED 2026-08-11

$1.7M

RICHARD ROBERT DELUCA JR

FILED 2026-08-10

$2.7M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

VanEck Pharmaceutical ETF

$124.5M POSITION · AS OF 2026-03-31

9.7%

Northern Trust US Equity ETF

$57.1M POSITION · AS OF 2026-03-31

7.5%

First Trust Nasdaq Pharmaceuticals ETF

$2.1M POSITION · AS OF 2026-03-31

7.4%

Hennessy Total Return Fund

$3.5M POSITION · AS OF 2026-04-30

7.0%

HARTFORD HEALTHCARE HLS FUND

$7.0M POSITION · AS OF 2026-03-31

6.7%

Smead Value Fund

$282.4M POSITION · AS OF 2026-02-27

6.4%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 649 registered trials, 226 still enrolling or running — a status change here is dated weeks before the press release

214

Phase 1

35 ACTIVE

126

Phase 2

50 ACTIVE

232

Phase 3

95 ACTIVE

Phase 4

2 ACTIVE

Early Phase 1

0 ACTIVE

Not applicable

2 ACTIVE

Multi-phase

42 ACTIVE

What changed recently

A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)

2026-09-04 · Recruiting → Active Not Recruiting

Phase 1

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combin

2026-09-04 · Completed → Terminated · Business Reasons

Phase 3

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macula

2026-09-03 · Not Yet Recruiting → Recruiting

Phase 3

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab i

2026-09-03 · Completion moved 2026-12-31 → 2027-12-31

Phase 1

A Study of V132 in Healthy Older Participants (V132-001)

2026-09-03 · Not Yet Recruiting → Recruiting

Phase 1

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

2026-09-03 · Active Not Recruiting → Completed

Phase 1

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Government contracts

USASpending.gov · total award ceilings over the contract's life, including awards won through subsidiaries — not annual revenue

Department Of Health And Human Services

IGF::OT::IGF · 2017-09-28

$236.3M

Department Of Health And Human Services

ERVEBO PROCUREMENT · 2024-09-30

$155.8M

FEDERAL AWARDS ≥ $25M IN THE LAST 90 DAYS · MATCHED VIA SAM.GOV PARENT REGISTRY

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Merck & Co., Inc., Employees Political Action Committee (Merck Pac)

CYCLE 2026 · $980K SPENT

$1.1M

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$65.0B	$64.2B	$60.1B	$59.3B
NET INCOME	$18.3B	$17.1B	$365.0M	$14.5B
EPS (DILUTED)	7.28	6.74	0.14	5.71
OPERATING CASH FLOW	$16.5B	$21.5B	$13.0B	$19.1B
CASH	$14.6B	$13.2B	$6.8B	$12.7B
LONG-TERM DEBT	$46.8B	$34.5B	$33.7B	$28.7B
BUYBACKS	$5.1B	$1.3B	$1.3B	$0
DIVIDENDS PAID	$8.2B	$7.8B	$7.4B	$7.0B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE